<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/world/takeda-engaged-antitrust-scheme-delay-generic-constipation-drug-us-jury-finds-2026-05-18/">Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds</a>
    </div>

      <div class="me-0 me-md-5">
        A ​U.S. jury on ‌Monday found that ​Takeda ​Pharmaceutical caused pharmacies, ⁠insurers, ​retailers and ​others to sustain about $885 million ​in ​damages delaying the ‌release ⁠of a generic version of ​its ​anti-constipation ⁠drug Amitiza ​through an ​anticompetitive ⁠scheme.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/takeda-cut-about-4500-jobs-fiscal-2026-it-steps-up-restructuring-2026-05-13/">Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring</a>
    </div>

      <div class="me-0 me-md-5">
        Japan&#39;s Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with ​a restructuring to centralize corporate functions and reduce ‌costs.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260510786927/en/Takeda-Announces-FY2025-Full-Year-Results-and-FY2026-Outlook-Highlighted-by-Excellent-Pipeline-Progress-and-Solid-FY2025-Results/">Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results</a>
    </div>

      <div class="me-0 me-md-5">
        OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% Y...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/takedas-immune-disease-drug-meets-main-goal-mid-to-late-stage-trial-2026-05-04/">Takeda&#39;s immune disease drug meets main goal of mid-to-late stage trial</a>
    </div>

      <div class="me-0 me-md-5">
        Takeda Pharmaceutical ​said its ‌experimental drug ​for ​primary immunodeficiency disease, ⁠a ​rare condition ​that weakens the ​immune ​system, has met ‌the ⁠main goal of a ​mid- ​to ⁠late-stage ​clinical trial.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260504944663/en/Takeda-Announces-Positive-Topline-Results-from-Pivotal-Phase-23-Clinical-Trial-of-TAK-881-in-Primary-Immunodeficiency-Disease-PID/">Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)</a>
    </div>

      <div class="me-0 me-md-5">
        OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260328889059/en/Takeda%E2%80%99s-Zasocitinib-Delivered-Rapid-and-Durable-Skin-Clearance-in-a-Convenient-Once-Daily-Pill-Affirming-Promise-to-Reshape-Psoriasis-Care/">Takeda&#39;s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care</a>
    </div>

      <div class="me-0 me-md-5">
        OSAKA, Japan &amp; CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda&#39;s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052">Takeda Pharmaceutical Co. Ltd. Sponsored ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/trumprx-lists-many-medicines-prices-higher-than-paid-uk-2026-03-18/">TrumpRx lists many medicines at prices higher than paid in UK</a>
    </div>

      <div class="me-0 me-md-5">
        U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, ​according to a Reuters comparison of publicly available prices.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Takeda-Pharmaceutical-Co-Ltd-Sponsored-ADR-US8740602052/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>